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Aims Mammalian target of rapamycin (mTOR), a central regulator of growth and metabolism, has tissue-specific functions
depending on whether it is part of mTOR complex 1 (mTORC1) or mTORC2. We have previously shown that
mTORC1 is required for adaptive cardiac hypertrophy and maintenance of function under basal and pressure-overload
conditions. In the present study, we aimed to identify functions of mTORC2 in the heart.
Methods
and results
Using tamoxifen-inducible cardiomyocyte-specific gene deletion, we generated mice deficient for cardiac rapamycin-
insensitive companion of mTOR (rictor), an essential and specific component of mTORC2. Under basal conditions,
rictor deficiency did not affect cardiac growth and function in young mice and also had no effects in adult mice. How-
ever, transverse aortic constriction caused dysfunction in the rictor-deficient hearts, whereas function was maintained
in controls after 1 week of pressure overload. Adaptive increases in cardiac weight and cardiomyocyte cross-sectional
area, fibrosis, and hypertrophic and metabolic gene expression were not different between the rictor-deficient and
control mice. In control mice, maintained function was associated with increased protein levels of rictor, protein kinase
C (PKC)bII, and PKCd, whereas rictor ablation abolished these increases. Rictor deletion also significantly decreased
PKC1 at baseline and after pressure overload. Our data suggest that reduced PKC1 and the inability to increase PKCbII
and PKCd abundance are, in accordance with their known function, responsible for decreased contractile performance
of the rictor-deficient hearts.
Conclusion Our study demonstrates that mTORC2 is implicated in maintaining contractile function of the pressure-overloaded
male mouse heart.
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1. Introduction
Recent studies have identified mammalian target of rapamycin (mTOR)
as an important regulator of cardiac adaptations to pressure overload.1
mTOR, an evolutionary conserved serine/threonine kinase belonging
to the phosphatidylinositol 3-kinase (PI3K)-related kinase family of
proteins, matches cell growth and metabolism with environmental re-
sources and other cues.2 Thus, it senses nutrient and energy status,
growth factors, oxygen levels and stress, and adapts a range of cellular
functions related to growth and metabolism correspondingly. In line
with its important regulatory function, mTOR overexpression is
protective in pressure-overloaded mouse hearts,3 whereas conditional
mTOR deletion causes cardiac dysfunction.4
mTOR has different functions depending on whether it is part of the
multiprotein complex termed mTOR complex 1 (mTORC1) or
mTORC2.5,6 We recently showed that raptor (regulatory-associated
protein of mTOR) is required for basal cardiac function and that adequate
mTORC1 activity is even more critical in the pressure-overloaded heart.
Reduced mTORC1 activity in raptor-deficient cardiomyocytes leads to
heart failure and death within 2 weeks of aortic constriction.7 While
increased autophagy and apoptosis as well as changed metabolism
were observed in the raptor-deficient hearts, one of the primary reasons
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for the observed dysfunction is reduced protein synthesis and a lack of
adaptive hypertrophy.7
Much less is known about mTORC2 owing to the unavailability of
selective inhibitors. Early work demonstrated that by phosphorylating
members of the AGC kinase family such as protein kinase C (PKC),
PKB/Akt, and SGK1, mTORC2 regulates cytoskeletal actin organiza-
tion, cell survival, and other processes.8 The availability of tissue-
specific knockout models for essential components of mTORC2
has recently given more insights into the in vivo functions of
mTORC2 for some tissues. Knockout of the mTORC2 component
rapamycin-insensitive companion of mTOR (rictor) in skeletal muscle
showed either no phenotype9 or impaired insulin-stimulated glucose
transport and enhanced glycogen synthase activity.10 Adipose-specific
rictor-deficient mice showed increased body size, an enlarged pan-
creas, and hyperinsulinaemia,10,11 whereas liver-specific rictor knock-
out mice revealed that mTORC2 regulates hepatic glucose and lipid
metabolism.12 mTORC2 was recently also shown to regulate size,
shape, and synaptic plasticity of neurons13,14 as well as oligodendrocyte
differentiation.15 These and other studies demonstrate that the func-
tions of mTORC2 are diverse and specific for the tissue or cell type
being analysed.
The mTORC1 inhibitor rapamycin is used as an immunosuppressant
and an anticancer drug, and the interest to use it for ageing-related dis-
ease including cardiac disease is also high. Notably, rapamycin does not
fully block mTORC116 and it was reported to activate mTORC2 and
Akt, which may be anti-apoptotic.17 On the other hand, long-term ra-
pamycin treatment can also inhibit mTORC2.18,19 Our present study
therefore aims to uncover the cardiac function of rictor/mTORC2
using a conditional knockout approach. We report that deletion of
rictor from cardiomyocytes inactivates mTORC2, but does not modify
basal cardiac function and geometry during postnatal growth and up to
an age of 54 weeks. However, rictor-deficient hearts perform less well
when challenged by aortic constriction-induced pressure overload,
despite the fact that their reactive hypertrophy is similar as in controls.
Our data suggest that mTORC2 is implicated in the contractile
response to pathological haemodynamic stress and further molecular
analyses point to PKCbII and PKCd as effectors of mTORC2 in our
model.
2. Methods
2.1 Animals
Male rictor knockout and control mice on a C57BL/6 background were
generated using tamoxifen-inducible Cre-recombinase under control of
the cardiomyocyte-specific a-myosin heavy chain (MHC) promoter.7
Transverse aortic constriction (TAC) and echocardiography were per-
formed as published, using ketamine/xylazine and isoflurane, respectively.7
Animal experiments were performed according to Guidelines for the Care
and Use of Laboratory Animals and with approval of the Swiss Cantonal
Authorities.
2.2 Cardiomyocyte isolation
Cardiomyocytes were isolated from control and cardiac rictor knockout
(rictor-cKO) mice at 12 weeks of age as published.20
2.3 Protein and RNA analysis
Equal amounts of protein or RNA extracted from tissues and cultured
cardiomyocytes were analysed by immunoblotting and quantitative
real-time PCR as reported.7
2.4 Microscopic analysis
Paraffin sections of 4% paraformaldehyde-fixed tissue were processed for
Picrosirius red staining to visualize fibrosis. Deoxynucleotidyl transferase
dUTP nick end-labelling (TUNEL) assay was performed using an in situ
apoptosis detection kit (Roche Diagnostics, Rotkreuz, Switzerland). Wheat
germ agglutinin (WGA) staining, collagen, and caspase-3 labelling were
done on cryosections fixed with 4% paraformaldehyde.7 Cross-sectional
areas were quantified by measuring at least 100 cardiomyocytes in three in-
dependent sections of 3–4 mice per group.
2.5 Statistical analysis
Data are presented as mean+ SEM. Differences in means were evaluated
with two-way ANOVA (P-values in text), followed by Sidak’s multiple com-
parisons tests (P-values in figures). For multiple measurements of the same
mice, repeated-measures ANOVA was used. All statistics was performed
with GraphPad Prism 6.0. P-values of ,0.05 were considered statistically
significant.
Detailed procedures, antibody sources, and buffer compositions are
provided in Supplementary material online.
3. Results
3.1 Rictor deficiency does not affect cardiac
weight, function, or geometry in adult mice
up to 54 weeks of age or in growing young
mice
To analyse the cardiac function of mTORC2, we generated cardiac-
specific rictor knockout mice by crossing mice containing the floxed
rictor gene9,21 with mice transgenic for inducible cre-recombinase
driven by the a-MHC promoter.22 The resulting rictorfl/fl a-MHC-
MerCreMerTg/0 micewere, at an age of 10weeks, injectedwith tamoxifen
to induce the deletion. These mice are hereafter referred to as
rictor-cKO mice. Control mice (rictor+/+ a-MHC-MerCreMerTg/0)
underwent the same tamoxifen treatment. 18 days after the tamoxifen
injections, rictor protein was lower in the rictor-cKO mice compared
with the control mice in cardiac muscle, but not in skeletal muscle.
Moreover, insulin-stimulated increases in Akt-pS473 were dramatically
impaired while 4E-BP1 phosphorylation was not affected in the
rictor-cKO hearts (Figure 1A). This confirms specificity of the deletion
and efficient inactivation of mTORC2, because Ser473 in the hydropho-
bicmotif (HM) of Akt is the best-established direct target of mTORC2. At
this time point after induction of the deletion, no cardiac functional or
geometric differences were revealed by ultrasound analysis between
the control and rictor-cKO mice. To evaluate the consequences of pro-
longed mTORC2 inactivation under basal conditions, we performed
echocardiography at 4, 6, 10, 16, and 25 weeks after tamoxifen to assess
cardiac parameters at 14, 16, 20, 26, and 35weeks of age (see Supplemen-
tary material online, Figure S1A and Table S1). At all time points, the ejec-
tion fraction (EF) and fractional shortening (FS) values of the rictor-cKO
mice were similar to those of control mice. Systolic and diastolic septum
and left ventricular (LV) posterior wall thickness, LV internal diameters,
and LV mass-to-body weight ratios were also indistinguishable over the
time period that these mice were followed. Consistently, post-mortem
analysis at the age of 35 weeks revealed no differences in ventricular
weight to tibia length ratios between the control and rictor-cKO mice.
In an independent experiment with a different batch of mice, we found
that even at 54 weeks of age, rictor-cKO mice were indistinguishable
from control mice (Table 1). Notably, at both 35 and 54 weeks, rictor
protein and mTORC2 activity, as assessed by the amount of Akt-pS473,
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were still significantly decreased (see Supplementary material online,
Figure S1B).
As mTOR and Akt have been implicated in growth regulatory me-
chanisms, we next deleted cardiac rictor in growing mice at 4 weeks
of age. We observed a normal increase in LV mass over time with no
differences between the rictor-cKO and control mice. Cardiac growth
was in proportion to whole body growth for both groups, as
LV mass-to-body weight ratios were identical over time (Figure 1B).
Moreover, EFs and all other echocardiographic parameters were nor-
mal during growth and up to an age of 16 weeks (see Supplementary
material online, Table S2). Thus, rictor deficiency does not affect
physiological cardiac growth in young mice and has no adverse
effects on cardiac function in healthy adult mice kept under laboratory
conditions up to 54 weeks of age, the latest time point analysed in
our study.
3.2 Rictor deficiency accelerates the
development of cardiac dysfunction after
aortic constriction
The above data show that despite significant changes in Akt phosphor-
ylation at Ser473, rictor-cKO mice have a virtually normal functional
cardiac phenotype.We reasoned that mTORC2may primarily function
as a modulator of cardiac function during cardiac stress and therefore
assessed the effect of rictor deficiency in the cardiac response to
pathological pressure overload induced by TAC. Rictor-cKO and con-
trol mice were assigned randomly to sham or TAC groups for surgery
at 18 or 19 days after tamoxifen. Echocardiography was performed be-
fore (see Supplementary material online, Table S3) and 1 week after
TAC (Figure 2A and Table 2). Prior to TAC, no differences were detect-
able between any of the experimental groups. In the control mice, 1
Figure 1 Baseline characterization of rictor-deficient mice at 18 days after induction of the deletion (A), and analysis of the consequences of rictor
deficiency in young growing mice (B). (A) At 18 days after tamoxifen, overnight-fasted male mice were stimulated with vehicle (‘fasted’) or insulin for 2 h,
sacrificed, and the left ventricle was dissected and snap-frozen for analysis by western blotting with antibodies as indicated. (B) Ultrasoundmeasurements
of EF, diastolic LV posterior wall thickness (LVPWd), LVEDD, and LVmass-to-body weight ratios are shown at the indicated ages. Rictor deletion at 10 (A)
and 4 (B) weeks of age. Rictor-cKO: tamoxifen-injected a-MHC-MerCreMer/rictorfl/fl (N ¼ 9). Controls: tamoxifen-injected a-MHC-MerCreMer/
rictor+/+ (N ¼ 4). Statistical analysis: repeated-measures ANOVA.
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week of TAC significantly increased the LV posterior and anteroseptal
wall thickness while not changing the LV end-systolic and end-diastolic
internal diameters. Moreover, the control mice maintained cardiac
function after TAC, as their EF and FS values were similar to those mea-
sured after sham surgery. In the rictor-cKO, however, TAC significantly
reduced EF and FS compared with sham-operated rictor-cKO or
TAC-operated control mice. The rictor-cKO mice had higher LV end-
diastolic diameters (LVEDD), an effect that was strongest at the end of
systole. Moreover, although after TAC the rictor-cKO mice displayed
increases in anteroseptal and LV posterior wall thickness, these
increases were less pronounced than those measured in control
mice. Taken together, these data indicate that the rictor-cKO mice
developed signs of eccentric LV hypertrophy with a decline in cardiac
function, whereas control mice were in the compensatory phase of
hypertrophy after 1 week of TAC.
3.3 Rictor deficiency does not affect
hypertrophy, fibrosis, or metabolic gene
expression after TAC
Post-mortem analysis at 1 week after TAC revealed that the ventricular
weight to tibia length ratios were not different between control and
rictor-cKOmice. Thus, both groups produced similar increases in cardiac
weight compared with the corresponding sham-operated groups
(Figure 2B). In line with an unaltered hypertrophic response, atrial natri-
uretic peptide (ANP) and brain natriuretic peptide (BNP) were induced
similarly in both groups (Figure 2B and D). TAC also increased skeletal
muscle actin and decreased a-MHC mRNA levels but again, these
changes happened irrespective of the absence or presence of rictor
(Figure 2C). Notably, b-MHC mRNA transcript levels were higher in
the rictor-cKO mice than in controls under sham and TAC conditions
(Figure 2C), although the effect did not reach statistical significance at
the protein level (Figure 2D). WGA labelling (Figure 3A), Picrosirius red
staining (Figure 3B), collagen I (Figure 3C) and collagen III immunolabelling
(not shown), as well as gene expression analysis (Figure 3D and see Sup-
plementary material online, Figure S2) showed that cardiomyocyte cross-
sectional areas, fibrosis, andmetabolic gene expressionwere not affected
by the rictor deletion. Thus, after 1 week of pressure overload, the altered
geometry and decreased function of the rictor-deficient hearts is not as-
sociated with any differences in cardiac weight, fibrosis, or hypertrophic
and metabolic gene expression compared with the control mice.
3.4 TAC increases rictor in control mice
and rictor deficiency reduces protein levels
of multiple PKC isoforms
Figure 4A shows that TAC caused a significant 1.65-fold increase in rictor
protein in control mice, an observation that per se provides support for a
role of rictor/mTORC2 in pressure-overload conditions. TAC also aug-
mented rictor protein somewhat in the knockout mice (P ¼ 0.12), which
is explained by the fact that the gene is not excised from all cardiac cells.22
To obtain insights into the mechanisms whereby mTORC2 supports car-
diac function during pressure overload, we proceeded to analyse the
phosphorylation state of several AGCkinases, direct targets ofmTORC2,
in cardiac protein extracts. Since rictor deficiency did not modify the
hypertrophic growth response to TAC, we directed our attention to
the PKC family of kinases, which have been implicated in metabolism
and contractility.23–25 One of the classical PKCs (cPKC), namely PKCa,
is a well-established direct target of mTORC2,26 and recent work shows
that several other PKCsmay also be regulated bymTORC2.13Given their
known importance in cardiac disease, we set out to analyse which of the
PKC isoforms were regulated in our TACmodel and towhat extent rictor
deficiency modified this regulation. Figure 4B shows that in control mice,
TAC increased total protein levels of the classical PKCbII as well as PKCd,
a novel PKC (nPKC) by 1.5- and 2.3-fold, respectively. For PKCbII, the
increase was paralleled by enhanced phosphorylation of its HM residue
Ser660 (Figure 4B and see Supplementary material online, Figure S3A).
An antibody to Thr638/641 in PKCa/bII revealed that phosphorylation
of this turn motif (TM) was also increased (Figure 4B). Probing with a
PKCbII-specific TM site antibody confirmed that this indeed concerned
phosphorylation of the PKCbII isoform and that the difference between
control and rictor-cKO mice was already visible prior to surgery (see
Supplementary material online, Figure S3B). As the above-mentioned
phosphorylation sites are all typical mTORC2 targets and the increases
in total and phosphorylated PKCs paralleled those observed for rictor
shown in Figure 4A, we next assessed whether rictor/mTORC2 is re-
quired for their increased abundance under pressure-overload condi-
tions. Indeed, the significant increases in PKCbII and PKCd protein
were absent in the rictor-cKO hearts and consistently, PKCbII-pS660
and -pT641 were lower in rictor-cKO than in control mice (Figure 4B).
While the rictor-cKO group had lower PKCa and -bII levels com-
pared with the control group, the abundance of PKCd appeared not
affected by rictor ablation under basal (sham) conditions (Figure 4B).
We also analysed PKC1, the other main nPKC expressed in the heart.
Its protein levels were lower in the rictor-cKO than in the correspond-
ing sham or TAC controls, and did not increase after TAC (Figure 4B
and see Supplementary material online, Figure S3C).
In conclusion, our observation that TAC increases PKCbII and PKCd
along with rictor in control, but not in the rictor-cKO hearts, suggests
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Echocardiographic parameters of control and
rictor knockout mice at 54 weeks of age
Control
(N 5 6)
Rictor-cKO
(N 5 5)
Echocardiography
Heart rate (b.p.m.) 500+28 563+16
Anteroseptal wall thickness (mm)
Diastole 0.97+0.04 0.82+0.07
Systole 1.36+0.05 1.17+0.11
LV wall thickness (mm)
Diastole 0.75+0.02 0.82+0.04
Systole 1.05+0.06 1.11+0.07
LV internal diameter (mm)
Diastole 4.11+0.05 4.11+0.2
Systole 2.88+0.04 3.03+0.24
Ejection fraction (%) 61.3+1.4 55.9+4.0
Fractional shortening (%) 32.6+1.0 29.0+2.7
Post-mortem analysis
Body weight (g) 40.6+1.6 39.8+2.2
Ventricular weight (VW, mg) 123.2+5.4 120.0+5.9
VW/body weight (mg/mm) 3.05+0.15 3.03+0.09
Rictor deletion was induced in a-MHC-MerCreMer/rictorfl/fl mice at the age of 10
weeks by an intraperitoneal injection with tamoxifen for 5 consecutive days. Controls
consisted of mice homozygous for the wild-type rictor gene (a-MHC-MerCreMer/
rictor+/+), injected with tamoxifen. Ultrasound analysis was performed at 44 weeks
after tamoxifen. N ¼ 5 for rictor-cKO and N ¼ 6 for control.
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that the inability to increase these isozymes contributes to the reduced
cardiac performance observed in our rictor-cKO mice under
pressure-overload conditions. As PKCbII was already affected under
basal conditions, its decrease is likely implicated directly in the develop-
ment of dysfunction. Although PKC1 was not increased after TAC, its
strongly reduced levels in rictor-cKO hearts may have contributed to
the dysfunction.
3.5 Rictor deficiency reduces Akt-pS473,
Akt-pS450, as well as total Akt1 and
2 protein, while increasing Akt-pT308
Akt is the most frequently analysed target of mTORC2 and serves as an
important survival kinase in the heart (for review, see Sussman et al.27).
Consistent with the baseline data obtained at 18 days after tamoxifen
(Figure 1A) phosphorylation of Akt at its HM residue, Ser473 was also
strongly reduced in the rictor-deficient hearts at 1 week after surgery,
i.e. 25 days after tamoxifen, confirming that mTORC2 was to a large
extent inactivated. Notably, total Akt protein was also lower in the
rictor-cKO mice than in controls. Antibodies specific for total Akt1
and Akt2 protein (Figure 4C) revealed that both isoforms were reduced
significantly. As previous studies have shown that mTORC2-mediated
TM phosphorylation determines the stability and thereby abundance of
Akt,28,29 we analysed Akt-pS450. Figure 4C shows that phosphorylation
of this site was indeed strongly diminished in the rictor-cKO hearts.
Notably, Akt phosphorylation at Thr308, thought to be key for Akt
activity,30 was not reduced despite a clear lack of phosphorylation at
Figure 2 Rictor deficiency causes cardiac dysfunction without changing hypertrophic responses after TAC. Rictor deletion was induced by tamoxifen at
10 weeks of age and TAC or sham surgery performed 18–19 days later. Ultrasound was performed before (see Supplementary material online, Table S1)
and 1 week after surgery (A), and the mice were sacrificed for molecular analysis immediately afterwards (B–D). (A) Echocardiography data of the EF,
LVEDD, and diastolic LV posterior wall thickness (LVPWd). (B) Post-mortem ventricular weight to tibia length ratios (VW/TL) and quantitative RT-PCR
analysis of ANP and BNP. (C) Quantitative RT-PCR analysis of b-MHC, a-MHC, and skeletal muscle (SkM) actin mRNA levels. (D) Western analysis of
ANP and b-MHC proteins. Rictor-cKO are tamoxifen-injected a-MHC-MerCreMer/rictorfl/fl mice (N ¼ 5 for sham, N ¼ 7 for TAC). Controls are
tamoxifen-injected a-MHC-MerCreMer/rictor+/+ mice (N ¼ 6 for sham, N ¼ 6 for TAC). Two-way ANOVA post hoc testing: **P, 0.01,
***P, 0.001 for TAC vs. sham; $P, 0.05, $$P, 0.01, $$$P, 0.001 for rictor-cKO vs. control.
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Ser473 and Ser450. Consistent with earlier studies,4,31 Akt-pT308 ap-
peared even somewhat higher in the rictor-cKO than in control mice
(P ¼ 0.035 in two-way ANOVA), although upstream of Akt-pT308
no compensatory change in phosphoinositide-dependent kinase 1
(PDK1) phosphorylation was observed (see Supplementary material
online, Figure S4A). In sham-operated mice, this went along with slightly
enhanced phosphorylation of the Akt targets GSK3b and TSC2 (see
Supplementary material online, Figure S4A). In an independent cohort
of mice sacrificed at 18 days after tamoxifen in the fasted or insulin-
stimulated state, rictor deficiency did not change phosphorylation of
the Akt targets AS160 and FoxO1/3a (see Supplementarymaterial online,
Figure S4B). Our results are consistent with the view that Akt phosphor-
ylation by mTORC2 is not required for its Thr308 phosphorylation by
PDK132 and with what has been described for liver,12 skeletal muscle,9
Purkinje cells,13 and other studies in which it was reported that Akt is still
activated to a significant extent in mTORC2-deficient cells. Our findings
show that also in the heart, the loss of mTORC2-mediated Akt
phosphorylation does not reduce Akt activity towards several of its
substrates.
3.6 Analysis of apoptosis in rictor-deficient
hearts and adult cardiomyocyte cultures
Akt is known to propagate the effects of PI3K within the nucleus via
FoxOs and thereby may regulate apoptosis.33,34 Some studies support
that mTORC2 is needed specifically for the function of Akt to phos-
phorylate FoxO, but not for other functions of Akt.35 A recent study
shows in cultured cardiomyocytes and ischaemic hearts that mTORC2
inactivation by Torin or shRNA enhances, whereas mTORC2 activa-
tion via PRAS40 decreases oxidative stress-induced apoptosis, and
suggests that this happens via Akt-pS473 and FoxO.36 We therefore
tested whether mTORC2 deficiency increased apoptosis in our model
by analysing cleaved caspase-3 and performing TUNEL assays. After
TAC, the rictor-cKO mice (N ¼ 6) had 2.2-fold more cleaved
caspase-3-positive cells than the control mice (N ¼ 5) and consistently,
they also contained more TUNEL-positive cells (Figure 5A and B). How-
ever, only very few apoptotic cells were detectable and these were all
part of the non-cardiomyocyte compartment of the heart as identified
by double labelling with antibodies to myomesin. Our finding that car-
diomyocyte apoptosis was not detectable in sections of the whole
heart was in apparent contrast with previous work,36 and we therefore
went on to analyse apoptosis by western blotting after isolation of car-
diomyocytes from the adult control and rictor-cKO hearts. Figure 5C
shows that rictor was below detection levels in this cardiomyocyte
fraction of the heart, which confirms efficiency and cardiomyocyte spe-
cificity of the deletion. Cleaved caspase-3 was higher in rictor-depleted
cardiomyocytes immediately (0 h) or 24 h after their isolation. These
data show that mTORC2 prevents apoptosis in adult cardiomyocytes,
at least during the isolation procedure of these cells, which is very likely
associated with hypoxic and/or other stress. Nevertheless, our obser-
vation that overall cardiac weight, fibrosis, and cardiomyocyte cross-
sectional areas were not changed by the deletion together with the
fact that we did not detect any apoptotic cardiomyocytes in the in
situ heart indicates that apoptosis is not a primary reason for the dys-
function measured in rictor-deficient pressure-overloaded hearts. This
conclusion is further supported by our observation that phosphory-
lated FoxO1/3 was not altered by the rictor deletion (see Supplemen-
tary material online, Figure S4B) and consistently, multiple FoxO target
genes (ERRa, MCD1, and CPT1b) were indistinguishable between con-
trol and rictor-cKO hearts (data not shown).
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Table 2 Physiological and echocardiographic parameters of control and rictor knockout mice at 1 week after sham or TAC
surgery
Control Rictor-cKO
Sham (N 5 7) TAC (N 5 6) Sham (N 5 5) TAC (N 5 7)
Echocardiography
Heart rate (b.p.m.) 539+25 495+14 473+16 514+13
Anteroseptal wall thickness (mm)
Diastole 0.77+0.01 1.04+0.02*** 0.73+0.02 0.89+0.03***,$$$
Systole 1.03+0.02 1.39+0.03*** 0.97+0.04 1.12+0.04*,$$$
LV posterior wall thickness (mm)
Diastole 0.78+0.01 1.15+0.03*** 0.72+0.02 0.92+0.03***,$$$
Systole 1.03+0.02 1.36+0.03*** 0.97+0.04 1.07+0.05*,$$$
LV internal diameter (mm)
Diastole 3.79+0.10 3.46+0.13 3.73+0.13 4.06+0.20$
Systole 2.67+0.10 2.55+0.16 2.70+0.18 3.38+0.26$$
Ejection fraction (%) 57.2+1.7 52.8+3.2 54.6+3.7 36.2+4.5**,$$
Fractional shortening (%) 29.6+1.1 26.6+2.0 27.9+2.4 17.3+2.3**,$$
Post-mortem analysis
Body weight (g) 29.0+0.4 26.6+1.1** 26.9+0.8 27.1+0.7
Ventricular weight (VW, mg) 112.4+2.0 143.7+4.2*** 103.9+3.1 135.9+4.1***
VW/tibial length (mg/mm) 6.17+0.13 7.84+0.24*** 5.69+0.18 7.49+0.22***
*P, 0.05, **P, 0.01, ***P, 0.001: TAC- vs. corresponding sham-operated group.
$P, 0.05, $$P, 0.01, $$$P, 0.001: knockout vs. corresponding control group.
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3.7 Rictor deficiency blunts signalling via
PRAS40, mTORC1, and rpS6
Next to the Akt targets GSK3b, TSC2, and AS160 described under
Section 3.5, reduced Akt levels in rictor-deficient hearts could, via
PRAS40 and TSC, diminish mTORC1 activity. Since changed signal-
ling via mTORC1 may, at least in part, explain the functional pheno-
type of the rictor-cKO mice, we tested whether mTORC2
inactivation modified signalling via mTORC1. Whereas Figure 6A
shows that phosphorylation of the mTORC1 targets 4E-BP1 and
UNC-51-like kinase 1 (ULK1) were not affected by rictor ablation,
Figure 6B shows a trend towards lower S6-pS240/244 in rictor-
deficient hearts (P ¼ 0.068 in two-way ANOVA), suggesting reduced
signalling via mTORC1/p70-S6K1. Consistently, mTOR phosphoryl-
ation at Ser2448, a target of p70-S6K1 indicative of mTORC1 activa-
tion, was decreased after rictor deletion (P ¼ 0.006 in two-way
ANOVA, Figure 6B). Furthermore, PRAS40, a target of Akt and com-
ponent and negative regulator of mTORC1, was less phosphorylated
in the rictor-cKO mice (P ¼ 0.011 in two-way ANOVA, Figure 6B).
Our findings suggest that mTORC2 may, possibly via Akt and
Figure 3 Rictor deficiency does not change cardiomyocyte cross-sectional areas or fibrosis after aortic constriction. Cardiac tissue of mice of Figure 2
was either frozen in OCT (A and C) or fixed in paraformaldehyde, followed by dehydration and embedding in paraffin (B), or snap-frozen in liquid ni-
trogen for isolation of RNA and quantitative RT-PCR analysis (D). (A) WGA staining (left) and quantitative analysis of the cardiomyocyte cross-sectional
area (right). (B) Picrosirius red staining for analysis of fibrosis. (C) Immunolabelling with an antibody to collagen I followed by a rhodamine-labelled sec-
ondary antibody. (B and C) TAC-operated mice. (D) Quantitative RT-PCR of collagen I and III and transforming growth factor (TGF)b to evaluate fibrosis
(N ¼ 5–6 mice per group). Two-way ANOVA post hoc testing: *P, 0.05; ***P, 0.001 for TAC vs. the corresponding sham control. The scale bars
represent 100 mm.
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PRAS40, regulate mTORC1-mediated p70-S6K1 and rpS6 phosphor-
ylation. We also analysed AMPKa, as it is known to independently re-
press mTORC1 signalling through specific phosphorylation sites on
mTOR, raptor, and TSC2 (reviewed in Shimobayashi and Hall37).
AMPKa phosphorylation was increased in the rictor-deficient hearts
(P ¼ 0.012 in two-way ANOVA). Thus, AMPK may have blocked
mTORC1 activity towards p70-S6K1 in parallel to PRAS40. Notably,
the observed increase in AMPKa phosphorylation is indicative of
increased AMP/ATP ratios, suggesting that energy availability is
decreased in the rictor-cKO hearts. Indicative of metabolic stress is
also the observed induction of b-MHC gene expression in the rictor-
deficient mice (Figure 2).
Figure 4 Effects of TAC and rictor ablation on AGC signalling at 1 week after surgery. Examples of western blots incubated with the antibodies as
indicated (left). Quantification after normalization to the corresponding loading controls (right). The normalized data are expressed relative to the
sham-operated controls. Control and rictor-cKO mice as in Figure 2. N ¼ 5–7 per group. Two-way ANOVA post hoc testing: *P, 0.05, **P, 0.01,
***P, 0.001 for TAC vs. sham; $P, 0.05, $$P, 0.01, $$$P, 0.001 for rictor-cKO vs. control.
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4. Discussion
4.1 Rictor/mTORC2 is implicated in the
response to pressure overload
Themain objective of the present study was to elucidate the function of
mTORC2 in the heart. Our experiments demonstrate that haemo-
dynamic stress causes cardiac dysfunction in mice deficient for rictor,
an essential component of mTORC2, whereas control mice with nor-
mal mTORC2 activity display maintained function. Cardiac mTORC2
inactivation does not cause any obvious basal phenotype during post-
natal growth or adulthood up to 54 weeks of age. Interestingly, TAC
increased overall ventricular weight in the rictor-cKO mice as much
as in the control mice, but increases in LV wall thickness were less pro-
nounced and associated with increased LV internal diameters, reminis-
cent of eccentric hypertrophy. Rictor deficiency did not affect any of
the TAC-induced hypertrophic markers ANP, BNP, smooth muscle ac-
tin, and skeletal muscle actin, nor did it modify metabolic gene expres-
sion or fibrosis. Taken together, our results indicate that mTORC2 is
important for contractile performance in acute pressure-overload con-
ditions, without affecting reactive hypertrophic responses.
4.2 Rictor/mTORC2 is required for
increased PKCbII and PKCd protein levels
during pressure overload
The role of mTORC2 during haemodynamic stress is further sup-
ported by our observation that rictor protein levels increase concomi-
tant with maintained function in pressure-overloaded control hearts.
This increase is paralleled by enhanced phosphorylation of PKCa and
PKCbII. Because mTORC2 has been implicated in the phosphorylation
of multiple PKC family members,13,26,28,38,39 our results suggest that
cardiac mTORC2 participates in the response to haemodynamic stress
via these effectors. The reduced phosphorylated levels of these PKCs
after cardiac rictor ablation consolidate this view.
Total protein levels of PKCbII, PKCd, and, albeit to a lesser extent,
PKCa (P ¼ 0.16) are also higher after TAC in control hearts, but not in
rictor-deficient hearts. Consistent with earlier work in murine embry-
onic fibroblasts, where evidence was provided that co-translational TM
site phosphorylation by mTORC2 regulates stability and thereby the
abundance of PKCa,27,39 we here show that enhanced TM phosphor-
ylation of PKCa and PKCbII after TAC is associated with their in-
creased abundance, whereas decreased phosphorylation of the same
sites after rictor deletion is associated with their reduced abundance.
Notably, the decrease in phosphorylated PKC was stronger than that
in total PKC, indicating that the remaining protein was less phosphory-
lated. Similarly, the strongly reduced Akt and PKC1 abundance in our
rictor-deficient hearts is very likely related to reduced mTORC2 phos-
phorylation, in line with previous mechanistic studies.13,28 On the other
hand, mTORC2 did not appear to regulate PKCd in MEFs28,39 or neu-
rons,13 and earlier work demonstrated TM autophosphorylation of
PKCd.40,41 Our data therefore suggest that PKCd stability may be regu-
lated in a cell type-specific manner. It remains to be provenwhether the
decrease in PKCd is explained by a direct mTORC2-mediated mechan-
ism because unlike Akt and other PKCs that we measured, PKCd ap-
peared not reduced under basal conditions. We therefore cannot
exclude the possibility that decreased PKCd abundance after TAC is
secondary to, for example, the observed cardiac or metabolic stress.
Speaking against this is that cardiac stress has previously been asso-
ciated with increased rather than decreased PKCd. Alternatively,
mTORC2-mediated PKC1 reductions could be responsible for the
lowered PKCd, as published previously,42 because PKC1 is an estab-
lished direct mTORC2 target.26,28,39
4.3 Functional consequences of reduced
PKCbII and PKCd after TAC
Phosphorylation of the three conserved serine/threonine residues on
cPKCs and nPKCs takes place shortly after synthesis and is needed
for their intracellular distribution, stability, and catalytic activity.43,44
These phosphorylation events cause a stable but still ‘closed’ inactive
enzyme conformation and prepare them for subsequent activation by
lipid second messengers, such as diacylglycerol (DAG) and Ca2+. In
pressure-overload models, stimulation of angiotensin AT1 and a1-
-adrenergic receptors will, via Gq and DAG, stimulate the PKCs. In-
creased PKC expression and activity was previously thought to cause
the pathological hypertrophy together with ERK1/2 and p38
stress-activated kinases. However, consistent with our observation
that decreased levels of two cPKCs were not associated with any
Figure 5 mTORC2 inactivation increases apoptosis in non-
myocyte cells of the heart. Cardiac tissue of the mice of Figure 2
was frozen in OCT (A) or fixed in paraformaldehyde, followed by de-
hydration and embedding in paraffin (B). (A) Immunostaining with an
antibody against cleaved caspase-3 fragment followed by an Alexa555-
labeled secondary antibody. Double labelling of the same section with
an antibody to myomesin followed by an Alexa488-labelled antibody
was performed to identify cardiomyocytes. (B) TUNEL assay was per-
formed on paraffin sections. (A and B) Nuclei were stained with DAPI.
For C, primary cardiomyocyte cultures were prepared from adult con-
trol and rictor cardiac knockout (cKO) mice and proteins extracted
immediately (0 h) or 1 day after the isolation (24 h). Caspase-3 was
analysed by western blotting.
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effects on the hypertrophic response, genetic ablation of the cPKC
family members does not prevent cardiac hypertrophy.45 Instead, the
cPKCs are today thought to be involved in the regulation of cardiac
contractility.23 Studies with PKC knockout mice have demonstrated
that the b and g isoforms are, in contrast to PKCa, positively affecting
contractility. Thus, PKCb/g null mice showmore severe failure, where-
as PKCa null mice are less susceptible to heart failure following long-
term pressure-overload or myocardial infarction injury.45 Based on
these studies, we think that our phenotype is related to the inability
of the rictor-deficient hearts to increase PKCbII and perhaps also
PKCg, which we did not test in the heart but was strongly decreased
after rictor ablation in neuronal tissue.13
Regarding the nPKCs, a study published during the revision of our
manuscript demonstrated that PKCd and PKC1 depress reactive
hypertrophy, but that it required deletion of both genes to reveal
this function, because redundancy masked the effect after ablation of
the individual genes. The lack of a phenotype under basal conditions
in our study with both nPKCs being strongly decreased after rictor
ablation is consistent with that study, in which combined embryonic
ablation of PKCd and PKC1 showed no phenotype under basal condi-
tions.35 The lack of a significant effect on pressure-overload hyper-
trophy in the rictor-deficient mice may be due to residual PKCd and
PKC1 protein, inherent to the inducible MerCreMer model that
we used.
Besides contractile deficiency, the decreased cardiac perform-
ance may be related to the energy resources available for contrac-
tion, as mTORC2 has been implicated in the regulation of
metabolism in various tissues.37,46 In support of this idea, AMPK
phosphorylation levels were increased in the rictor-cKO hearts
indicative of a reduced ATP availability. Moreover, b-MHC expres-
sion was induced, which, as this isoform generates force in an ener-
getically more economic manner than the a-isoform, may represent
a compensatory energy-preserving effort after rictor ablation. Akt2
regulates Glut4 translocation to the sarcolemma, a process that is
enhanced during the cardiac pressure-overload response to ensure
that energy supplies match the increased work. However, although
Akt2 abundance was strongly reduced in the rictor-cKO hearts, the
phosphorylation of its downstream mediator AS160 was not
affected (see Supplementary material online, Figure S4B). Finally,
the lack of a robust PKCd increase after TAC, possibly secondary
to decreased PKC1,42 may explain metabolic insufficiency after
rictor ablation, because it has been shown previously that hearts
lacking PKCd lose their capacity to adapt metabolically.47,48 In con-
clusion, our data suggest that the lacking increases in PKCbII and
Figure 6 Effect of rictor deletion on mTORC1, PRAS40, and AMPK. Examples of western blots incubated with antibodies as indicated (left). Quan-
tification after normalization to the corresponding loading controls (right). The normalized data are expressed relative to the sham-operated controls.
Control and rictor-cKOmice as in Figures 2 and 4. N ¼ 5–7 per group. Two-way ANOVA post hoc testing: *P, 0.05, **P, 0.01, ***P, 0.001 for TAC
vs. sham; $P, 0.05 for rictor-cKO vs. control.
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PKCd contributed to the dysfunction observed after pressure over-
load for the rictor-deficient hearts.
4.4 Reduced phosphorylation of Akt at
Ser473 and Ser450 after rictor ablation does
not reduce Akt substrate phosphorylation
Next to the above-discussed PKCs, the protein abundance of the
best-established mTORC2 target Akt was reduced in the rictor-cKO
mice and this applies to Akt1 as well as Akt2. Because Akt was not
increased in our TAC model, its reduced expression is most likely
not a primary cause of the dysfunction measured in the rictor-cKO
mice. The lack of a functional or morphological phenotype under
physiological conditions in growing and adult mice suggests that the
residual protein amounts were sufficient for normal cardiac function
or that a high level of redundancy in cardiac signalling exists and alter-
nate pathways compensate for the deletion. The latter possibility is
supported by the fact that phosphorylation of Akt at Thr308 was not
impaired and that the Akt targets GSK3b, TSC, and AS160 mirrored
the Akt-pT308 levels, indicating normal Akt activity under basal condi-
tions. These results imply that the mTORC2-mediated Akt phosphor-
ylation is not essential for basal cardiac function. Consistently, cardiac
deletion of mTOR4 caused a basal phenotype that was very similar to
that of mice in which raptor was lacking,7 which indicates that mTOR
acts predominantly as part of mTORC1. Similar observations were
noted for other organs, including skeletal muscle,9,10 kidney,49 or adi-
pose tissue11 in all of which rictor deficiency does not cause any strong
baseline phenotype. Along similar lines, mTORC2-mediated HM site
phosphorylation appears not essential for the growth regulatory activ-
ity of Akt at physiological levels of insulin stimulation.50 The latter study
suggests that only the maximal levels of Akt activity are limited in the
absence of HM phosphorylation, for example, when insulin stimulation
is increased.50 In analogy, our data obtained with the TAC model sug-
gest that in the heart, the mTORC2-mediated phosphorylation be-
comes functionally important when mTORC2 targets are significantly
activated, which we demonstrated for PKCbII and PKCd, but not for
Akt. It is of note that our study was performed with male mice. Given
the known effect of female hormones on Akt signalling, it remains to be
demonstrated whether mTORC2 deficiency impacts one or more
targets of Akt in the female heart.
4.5 mTORC2 inactivation does not modify
physiological or pathological cardiac growth
Our previous work shows that mTORC1 is essential for the cardiac
adaptation to pressure overload with protein synthesis inherent to car-
diomyocyte hypertrophy being one of the prior mechanisms impli-
cated.7 Upstream of mTORC1 and downstream of mTORC2 Akt
can activate protein translation via TSC1/TSC2 and Rheb. Akt regulates
normal postnatal cardiac growth,51 it may get activated by pressure
overload,52 and transgenic overexpression of active Akt1 induces
cardiac hypertrophy.53,54 Whether or not mTORC2, via Akt or other
pathways, contributes to cardiac growth responses was unclear at the
onset of our study. As rictor deletion neither affected cardiac weight and
cardiomyocyte cross-sectional areas after TAC, nor changed physio-
logical postnatal cardiac growth, we conclude that mTORC2 is not
required for cardiac protein synthesis. This is further supported by
our observation that 4E-BP1, main mediator of protein synthesis down-
stream of mTORC1, was increased after TAC in the rictor-cKO as
much as in control mice. Moreover, Akt-pT308 was increased along
with enhanced phosphorylation of targets involved in growth re-
sponses, such as TSC2 andGSK3b. In contrast, rictor ablation decreased
S6K1 phosphorylation. While this effect may be secondary to de-
creased PKC activity,41,41,55,56 it had no consequences for cardiac
weight or cardiomyocyte cross-sectional area in our model, consistent
with earlier work.57 Thus, the heart behaves like several other organs
from which rictor has been removed without affecting an increase in
organ weight, including skeletal muscle,9,10 adipose tissue,11 and
kidney.49 We conclude that increased global protein synthesis intrinsic
to physiological growth or pathological cardiac hypertrophy does not
depend on mTORC2.
Taken together, our study points to a beneficial function of
mTORC2 in the heart during haemodynamic stress. We identified
several kinases that were reduced in rictor-deficient hearts. As cardiac
dysfunction occurred only after haemodynamic stress, we conclude
that the kinases that were increased concomitant to rictor in control
but not in rictor-cKO hearts, namely PKCbII and -d, are implicated in
the beneficial effects of mTORC2. As several compounds inhibiting
both mTOR complexes are in clinical trials for the treatment of cancer,
special attention should be paid in these studies to patients with con-
current cardiovascular diseases such as hypertension or valve disease.
On the other hand, our insights into cardiac mTORC2 signalling may
also open new avenues for the treatment of cardiac disease.
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